Hepatitis C: State of Medicaid Access Report Card

Wyoming



Grade	Recommendations to Improve Patient Access
C	• Remove prior authorization for HCV treatment. • Remove drug screening requirement. • Remove limit of one course of treatment per lifetime. • Remove additional restrictions as described below.

State Overview

As of October 2022, 80,623 individuals were enrolled in Medicaid and CHIP. Wyoming has not expanded coverage to low-income adults.[1] It is estimated that as of 2016, 3,700 people were living with HCV in Wyoming.[2] All Medicaid beneficiaries receive care through the Fee-For-Service (FFS) program. Wyoming does not contract with any Managed Care Organizations (MCOs).[3] Thus, Hepatitis C coverage requirements are uniform through the program.

The Wyoming Medicaid Preferred Drug List designates Mavyret and sofosbuvir/velpatasvir as preferred regimens.[4]

Deductions		Policy
Prior Authorization	-8	Prior authorization is required for all HCV treatment regimens.[5]
Fibrosis Restrictions		Wyoming Medicaid does not impose fibrosis restrictions.[6]
Substance Use Restrictions	-4	Wyoming Medicaid imposes substance use restrictions. Wyoming requires drug screening within 30 days of treatment and may require additional information prior to authorization in the case of a positive test for illicit drugs.[7]
Prescriber Restrictions		Wyoming Medicaid does not impose prescriber restrictions.[8]
Retreatment Restrictions	-8	Wyoming Medicaid appears to impose retreatment restrictions. The Prior Authorization Form notes that Wyoming allows only one course of treatment per lifetime.[9] However, the Preferred Drug List notes that "SVR 12 will be required for consideration for retreatment."[10]
Access in Managed Care		Wyoming does not contract with MCOs.[11]
Additional Restrictions	-4	Wyoming Medicaid imposes additional restrictions as follows:[12] • Documentation of HCV genotype. • Documentation of adherence counseling: Wyoming Medicaid requires the prescriber to document patient's ability to adhere to treatment via a psychosocial readiness survey, PREP-C. Additionally, Wyoming Medicaid requires a commitment form to be signed by the patient and provider. The form notes that: "Non-compliance with the prescribed Hepatitis C regimen may put the client in jeopardy for denial of coverage in the future."[13]
Total Deductions -24		**Total Score [100-Deductions]** 76	**Grade** C

Contact Your State Officials

Medicaid Office:[14] Lee Grossman, Medicaid Director, Wyoming Department of Health; Mailing Address: Wyoming Department of Health, 3001 E. Pershing Blvd., Suite 125, Cheyenne, WY 82001; Phone Number: 1-855-294-2127

Pharmacy & Therapeutics Committee:[15] Mailing Address: Wyoming Drug Utilization Review (WY-DUR), Dept. 3375, 1000 E. University Ave., Laramie, WY 82071; Phone: 307-766-6750; Email: alewis13@uwyo.edu.

Key Sources

Preferred Drug List: Wyoming Medicaid, Preferred Drug List (Jan. 20, 2023)
Clinical Criteria: Wyoming Medicaid does not publish clinical criteria.
Prior Authorization Form: Wyoming Medicaid, Prior Authorization Form and Patient Commitment Form (Nov. 26, 2019)

---

[1] Centers for Medicare & Medicaid Services, Medicaid & Chip in Wyoming, https://perma.cc/57AW-HYGT.
[2] HepVu, Local Data: Wyoming, https://perma.cc/DLR3-QFJ8.
[3] Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (Jul. 2, 2022), https://perma.cc/EMN8-QR8B.
[4] Preferred Drug List.
[5] Preferred Drug List.
[6] Prior Authorization Form.
[7] Prior Authorization Form.
[8] Prior Authorization Form.
[9] Prior Authorization Form.
[10] Preferred Drug List.
[11] Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (Jul. 2, 2022), https://perma.cc/EMN8-QR8B.
[12] Prior Authorization Form.
[13] Prior Authorization Form.
[14] Wyoming Department of Health, Apply for Medicaid: https://perma.cc/JJS8-M2HE.
[15] Wyoming Drug Utilization Review, P&T Committee Past Meeting Minutes: https://perma.cc/WE8B-JEW6.